BAJAJ BROKING

Notification close image
No new Notification messages
card image
Amanta Healthcare Ltd IPO
Apply for the Amanta Healthcare Ltd IPO through UPI in Just minutes
delete image
card image
Start your SIP with just ₹100
Choose from 4,000+ Mutual Funds on Bajaj Broking
delete image
card image
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
delete image
card image
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
delete image
card image
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
delete image

0

540729

VANTABIO

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

Vanta Bioscience Limited Share Price Update

As of the latest trading session, Vanta Bioscience Limited share price is currently at ₹ 23.18, which is up by ₹ 0.00 from its previous closing. Today, the stock has fluctuated between ₹ 23.18 and ₹ 23.18. Over the past year, Vanta Bioscience Limited has achieved a return of -52.69 %. In the last month alone, the return has been -18.06 %. Read More...

Investment Returns

Over 1 Month -18.06% Over 3 Months -8.34% Over 6 Months -27.44% Over 1 Year -52.69%
demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

Vanta Bioscience Limited fundamentals


  • Market cap (Cr)

  • P/E Ratio (TTM)

  • Beta

  • Book Value / share

  • Return on equity

    %

  • EPS (TTM)

  • Dividend yield

    %

  • Net profit/quarter (Cr)

info icon alternate text
  • Market cap (Cr)

    14.60

  • P/E Ratio (TTM)

    -5.51

  • Beta

    0.58

  • Book Value / share

    27.14

  • Return on equity

    0.05%

  • EPS (TTM)

    0.00

  • Dividend yield

    %

  • Net profit/quarter (Cr)

    -1.22

info icon alternate text

Vanta Bioscience Limited Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars MAR 2023 (Values in Cr)
Revenue 1.76
Operating Expense 0.00
Net Profit -1.22
Net Profit Margin (%) -69.31
Earnings Per Share (EPS) 0.00
EBITDA 0.00
Effective Tax Rate (%) 0.00
Particulars DEC 2022 (Values in Cr)
Revenue 1.71
Operating Expense 3.21
Net Profit -1.51
Net Profit Margin (%) -88.30
Earnings Per Share (EPS) -2.39
EBITDA 0.32
Effective Tax Rate (%) -0.67
Particulars DEC 2021 (Values in Cr)
Revenue 0.00
Operating Expense 0.00
Net Profit 0.00
Net Profit Margin (%) 0.00
Earnings Per Share (EPS) 0.00
EBITDA 0.00
Effective Tax Rate (%) 0.00
Particulars MAR 2025 (Values in Cr)
Revenue 1.13
Operating Expense 3.88
Net Profit -2.66
Net Profit Margin (%) -235.39
Earnings Per Share (EPS) -4.21
EBITDA -1.62
Effective Tax Rate (%) 2.20
Particulars MAR 2024 (Values in Cr)
Revenue 8.56
Operating Expense 8.55
Net Profit 0.05
Net Profit Margin (%) 0.58
Earnings Per Share (EPS) 0.08
EBITDA 3.70
Effective Tax Rate (%) -25.00
Particulars MAR 2023 (Values in Cr)
Revenue 5.17
Operating Expense 10.01
Net Profit -4.24
Net Profit Margin (%) -82.01
Earnings Per Share (EPS) -6.71
EBITDA 0.14
Effective Tax Rate (%) -0.71
Particulars MAR 2022 (Values in Cr)
Revenue 9.35
Operating Expense 9.37
Net Profit 0.08
Net Profit Margin (%) 0.85
Earnings Per Share (EPS) 0.12
EBITDA 3.57
Effective Tax Rate (%) 42.85
Particulars MAR 2021 (Values in Cr)
Revenue 10.04
Operating Expense 9.46
Net Profit 0.47
Net Profit Margin (%) 4.68
Earnings Per Share (EPS) 0.75
EBITDA 3.92
Effective Tax Rate (%) 21.31
Particulars MAR 2024 (Values in Cr)
Book Value / Share 24.08
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 3.61
EBITDA Margin 14.61
Particulars MAR 2023 (Values in Cr)
Book Value / Share 27.75
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 2.46
EBITDA Margin -27.07
Particulars MAR 2022 (Values in Cr)
Book Value / Share 38.03
ROE % 0.54
ROCE % 3.99
Total Debt to Total Equity 1.69
EBITDA Margin 40.14
Particulars MAR 2021 (Values in Cr)
Book Value / Share 37.89
ROE % 1.90
ROCE % 5.42
Total Debt to Total Equity 1.13
EBITDA Margin 39.64
Particulars MAR 2020 (Values in Cr)
Book Value / Share 37.18
ROE % 4.42
ROCE % 8.62
Total Debt to Total Equity 0.67
EBITDA Margin 31.68
Particulars MAR 2024 (Values in Cr)
Book Value / Share 31.36
ROE % 0.05
ROCE % 5.24
Total Debt to Total Equity 1.29
EBITDA Margin 42.76
Particulars MAR 2023 (Values in Cr)
Book Value / Share 31.28
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 1.06
EBITDA Margin 2.90
Particulars MAR 2022 (Values in Cr)
Book Value / Share 38.01
ROE % 0.33
ROCE % 5.24
Total Debt to Total Equity 0.79
EBITDA Margin 38.18
Particulars MAR 2021 (Values in Cr)
Book Value / Share 37.88
ROE % 1.99
ROCE % 6.75
Total Debt to Total Equity 0.66
EBITDA Margin 39.04
Particulars MAR 2020 (Values in Cr)
Book Value / Share 37.14
ROE % 4.29
ROCE % 8.87
Total Debt to Total Equity 0.60
EBITDA Margin 31.40
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 0.16
Total Assets 85.39
Total Liabilities 85.39
Total Equity 12.97
Share Outstanding 6312000
Price to Book Ratio 2.04
Return on Assets (%) -2.71
Return on Capital (%) -3.13
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 0.09
Total Assets 84.70
Total Liabilities 84.70
Total Equity 18.92
Share Outstanding 6312000
Price to Book Ratio 1.84
Return on Assets (%) -7.65
Return on Capital (%) -8.52
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 0.22
Total Assets 81.40
Total Liabilities 81.40
Total Equity 29.34
Share Outstanding 6312000
Price to Book Ratio 2.89
Return on Assets (%) 0.10
Return on Capital (%) 0.13
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 2.65
Total Assets 69.62
Total Liabilities 69.62
Total Equity 26.22
Share Outstanding 6312000
Price to Book Ratio 4.30
Return on Assets (%) 0.64
Return on Capital (%) 0.77
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 0.19
Total Assets 48.57
Total Liabilities 48.57
Total Equity 24.45
Share Outstanding 6312000
Price to Book Ratio 2.45
Return on Assets (%) 2.06
Return on Capital (%) 2.51
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 0.14
Total Assets 52.90
Total Liabilities 52.90
Total Equity 19.79
Share Outstanding 6312000
Price to Book Ratio 2.04
Return on Assets (%) 0.09
Return on Capital (%) 0.11
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 0.06
Total Assets 51.63
Total Liabilities 51.63
Total Equity 19.74
Share Outstanding 6312000
Price to Book Ratio 1.84
Return on Assets (%) -8.20
Return on Capital (%) -9.31
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 0.06
Total Assets 50.39
Total Liabilities 50.39
Total Equity 23.98
Share Outstanding 6312000
Price to Book Ratio 2.89
Return on Assets (%) 0.15
Return on Capital (%) 0.18
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 0.06
Total Assets 46.24
Total Liabilities 46.24
Total Equity 23.91
Share Outstanding 6312000
Price to Book Ratio 4.30
Return on Assets (%) 1.01
Return on Capital (%) 1.14
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 0.08
Total Assets 41.58
Total Liabilities 41.58
Total Equity 23.44
Share Outstanding 6312000
Price to Book Ratio 2.45
Return on Assets (%) 2.35
Return on Capital (%) 2.74
Particulars MAR 2024 (Values in Cr)
Net Income -8.82
Cash from Operations 2.68
Cash from Investing -3.31
Cash from Financing 0.69
Net change in Cash 0.06
Free Cash Flow 6.08
Particulars MAR 2023 (Values in Cr)
Net Income -10.26
Cash from Operations -0.62
Cash from Investing -5.90
Cash from Financing 6.40
Net change in Cash -0.12
Free Cash Flow 28.06
Particulars MAR 2022 (Values in Cr)
Net Income 0.22
Cash from Operations 5.27
Cash from Investing -17.18
Cash from Financing 9.53
Net change in Cash -2.42
Free Cash Flow 5.61
Particulars MAR 2021 (Values in Cr)
Net Income 0.58
Cash from Operations 6.97
Cash from Investing -22.19
Cash from Financing 17.78
Net change in Cash 2.45
Free Cash Flow 7.82
Particulars MAR 2020 (Values in Cr)
Net Income 1.34
Cash from Operations 2.34
Cash from Investing -7.35
Cash from Financing 2.17
Net change in Cash -3.07
Free Cash Flow 2.68
Particulars MAR 2024 (Values in Cr)
Net Income 0.04
Cash from Operations 4.54
Cash from Investing -1.66
Cash from Financing -2.80
Net change in Cash 0.07
Free Cash Flow 4.55
Particulars MAR 2023 (Values in Cr)
Net Income -4.20
Cash from Operations 0.64
Cash from Investing -2.53
Cash from Financing 1.88
Net change in Cash 0.00
Free Cash Flow 3.17
Particulars MAR 2022 (Values in Cr)
Net Income 0.13
Cash from Operations 6.70
Cash from Investing -8.05
Cash from Financing 1.37
Net change in Cash 0.00
Free Cash Flow 14.75
Particulars MAR 2021 (Values in Cr)
Net Income 0.60
Cash from Operations 11.00
Cash from Investing -9.85
Cash from Financing -1.07
Net change in Cash -0.02
Free Cash Flow 11.88
Particulars MAR 2020 (Values in Cr)
Net Income 1.28
Cash from Operations 3.16
Cash from Investing -1.34
Cash from Financing -1.80
Net change in Cash -0.19
Free Cash Flow 3.51
Company Name Price P/E P/B Market Cap 52 Week Low/High
BRITANNIA INDUSTRIES LTD 5845.10 64.18 32.32 140789.93 4506.50 / 6473.10
NESTLE INDIA LIMITED 1174.20 76.20 56.46 226422.67 1057.50 / 1388.50
FOODS & INNS LIMITED 89.60 15.66 1.22 657.80 75.20 / 147.80
HINDUSTAN UNILEVER LTD. 2648.20 58.51 12.59 622218.76 2136.00 / 3034.50
Company Name Price P/E P/B Market Cap 52 Week Low/High
BRITANNIA INDUSTRIES LTD 5845.10 66.19 36.22 140789.93 4506.50 / 6473.10
COLGATE PALMOLIVE LTD. 2360.40 46.07 38.57 64199.49 2151.00 / 3893.00
NESTLE INDIA LIMITED 1174.20 75.27 54.99 226422.67 1057.50 / 1388.50
FOODS & INNS LIMITED 89.60 14.74 1.21 657.80 75.20 / 147.80

Vanta Bioscience Limited Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
23.18 -4.99 redarrow
red-green-graph indicator
0 Bearish
16 Bullish
  • 5 Days 24.80
  • 26 Days 26.30
  • 10 Days 25.70
  • 50 Days 26.70
  • 12 Days 26.00
  • 100 Days 29.80
  • 20 Days 26.30
  • 200 Days 38.60
23.18 PIVOT

First Support

23.18

First Resistance

23.18

Second Support

23.18

Second Resistance

23.18

Third Support

23.18

Third Resistance

23.18

RSI

36.99

ADX

23.30

MACD

-0.37

Williams % R

-100.00

Commodity Channel Index (CCI)

-151.99

Date

2025-08-29

Week

2250.00

Same Day

750.00

Month

1350.00

1 Year

0.59

3 Year

0.41

Over 1 Month

-18.06%

down

Over 1 Year

-52.69%

down

Over 3 Months

-8.34%

down

Over 3 Years

-36.97%

down

Over 6 Months

-27.44%

down

Over 5 Years

-32.13%

down

Transparent Pricing, 360° Services

Choose a plan that best suits your goals & needs.

greenshadow greenshadow redshadow pricing-pack Freedom Pack
₹20/order 14.99% p.a. MTF
tick Expert Stock Research tick Online Customer Support

Subscription Charge : FREE

greenshadow greenshadow redshadow pricing-pack

Professional Pack

₹10/order 11.99% p.a. MTF
tick Expert Stock Research tick Online Customer Support

Subscription Charge : 2500 Yearly

50% Brokerage Savings
greenshadow greenshadow redshadow pricing-pack

Signature

0.2% 11.99% p.a. MTF
tick Dedicated Relationship Manager tick Customised Brokerage Support tick Expert Stock Research tick Experienced Dealer Support

Vanta Bioscience Limited shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Name Shares Category

News

Left Arrow
Right Arrow

Vanta Bioscience Limited corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
[-] [-] [-] [-] [-]
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
[-] [-] [-] [-] [-]
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]

Vanta Bioscience Limited Share Price

Vanta Bioscience Limited was originally incorporated as a Private Limited Company on 29th April 2016 with the name 'Vanta Bioscience Private Limited'. The Company converted into a Public Limited Company and the name was changed to 'Vanta Bioscience Limited' on 17th March 2017.

The Company is presently engaged in the business of Preclinical Activities. The Company provides risk assessment services for evaluating safety of the Active Pharmaceutical Ingredients (API), excipients, extractable and leachables including pharmaceutical impurities resulting due to manufacturing process or due to degradation of product.

The Company is established as a center of excellence for GLP toxicology and safety assessment offering services in India and across the globe. One of the major services of VBS is conducting variety of in vitro (cell, tissue and organisms) and in vivo (animal) toxicology studies for its diverse clients as per various regulatory requirements from across the world. Toxicology is a branch of biology, chemistry, and pharmacology concerned with the study of the adverse effects of chemicals on living organisms. It also studies the harmful effects of chemical, biological and physical agents in biological systems that establish the extent of damage in living organisms.

The Company purchased preclinical CRO facility at Gummidipundi, Chennai from Kemin Industries South Asia Private Limited which was named as 'Vanta Bioscience' (a toxicology division and commenced commercial activities in April, 2017. VBS has state of the art facilities and infrastructure necessary for conduct of all kind of toxicology studies for Chemicals, Pharmaceuticals, Cosmetics, Agrochemicals like Pesticides, Insecticides, Excipients, Novel Feed Additives.

In addition, the Company conducts preclinical proof-of-concept (PoC) studies for novel pharmaceuticals and products intended for new indications in variety of animal models of human diseases through a robust process of validation.

In September 2017, the Company came up with a Public Issue of 15,12,000 Equity Shares by raising money from public aggregating to Rs 7.56 Crore.

In 2018-19, Vanta Clinical Research Limited and Vayam Research Solutions Limited became the subsidiaries of the Company.

Parent organization Indian Private
NSE symbol [-]
Founded 2016
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of Vanta Bioscience Ltd?

Answer Field

Vanta Bioscience Ltd share price is for NSE ₹ 0.00 & for BSE ₹ 23.18 as on Aug 29 2025 12:00 AM.

What is the Market Cap of Vanta Bioscience Ltd Share?

Answer Field

The market cap of Vanta Bioscience Ltd for NSE ₹ 0.00 & for BSE ₹ 14.60 as on Aug 29 2025 12:00 AM.

What is the 52 Week High and Low of Vanta Bioscience Ltd?

Answer Field

The 52 Week High and Low of Vanta Bioscience Ltd for NSE is ₹ 0.00 and ₹ 0.00 and for BSE is ₹ 56.00 and ₹ 19.08.

What is 1 year return for Vanta Bioscience Ltd?

Answer Field

The 1 year returns on the stock has been -52.69%.

What is the P/E Ratio of Vanta Bioscience Ltd Share?

Answer Field

As on Aug 29 2025 12:00 AM the price-to-earnings (PE) ratio for Vanta Bioscience Ltd share is -5.51.

What is the PB ratio of Vanta Bioscience Ltd Share?

Answer Field

As on Aug 29 2025 12:00 AM, the price-to-book (PB) ratio for Vanta Bioscience Ltd share is 27.14.

How to Buy Vanta Bioscience Ltd Share?

Answer Field

You can trade in Vanta Bioscience Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Vanta Bioscience Ltd Share on Bajaj Broking App?

Answer Field

To buy Vanta Bioscience Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Vanta Bioscience Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

close-image

Authorise with OTP

Enter the 4-Digit OTP sent to
edit
OTP expires in 00:59
close-image

Get Free Demat Account*

+91